The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Open accessAbstract
Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can mediate regression of metastatic melanoma; however, TILs are a heterogeneous population, and there are no effective markers to specifically identify and select the repertoire of tumor-reactive and mutation-specific CD8⁺ lymphocytes. The lack of biomarkers limits the ability to study these cells and develop strategies to enhance clinical efficacy and extend this therapy to other malignancies. Here, we evaluated unique phenotypic traits of CD8⁺ TILs and TCR β chain (TCRβ) clonotypic frequency in melanoma tumors to identify patient-specific repertoires of tumor-reactive CD8⁺ lymphocytes. In all 6 tumors studied, expression of the inhibitory receptors programmed cell death 1 (PD-1; also known as CD279), lymphocyte-activation gene 3 (LAG-3; also known as CD223), and T cell immunoglobulin and mucin domain 3 (TIM-3) on CD8⁺ TILs identified the autologous tumor-reactive repertoire, including mutated neoantigen-specific CD8⁺ lymphocytes, whereas only a fraction of the tumor-reactive population expressed the costimulatory receptor 4-1BB (also known as CD137). TCRβ deep sequencing revealed oligoclonal expansion of specific TCRβ clonotypes in CD8⁺PD-1⁺ compared with CD8⁺PD-1- TIL populations. Furthermore, the most highly expanded TCRβ clonotypes in the CD8⁺ and the CD8⁺PD-1⁺ populations recognized the autologous tumor and included clonotypes targeting mutated antigens. Thus, in addition to the well-documented negative regulatory role of PD-1 in T cells, our findings demonstrate that PD-1 expression on CD8⁺ TILs also accurately identifies the repertoire of clonally expanded tumor-reactive cells and reveal a dual importance of PD-1 expression in the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“We measured cell surface expression of differentiation markers CD62L, CD45RO, CD27, and CD57 (31), inhibitory receptors PD-1, LAG-3, TIM-3, and BTLA, typically expressed on chronically stimulated CD8+ T cells (23, 24, 32, 33), and costimulatory receptor 4-1BB (28, 34) and IL-2 receptor alpha CD25 (35), which can be up…”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Self-citationRosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Self-citationMolecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function
Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J. D., Suresh, M., Altman, J. D., & Ahmed, R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2205 · Cited by 1,978
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Self-citationRobbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Self-citationExpression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Self-citationMolecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,354
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Self-citationThe role of TNF superfamily members in T-cell function and diseases
Croft, M. (2009) · Nature Reviews Immunology · doi:10.1038/nri2526 · Cited by 920
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845
Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines
Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., & Slingluff, C. L. (1994) · Science · doi:10.1126/science.7513441 · Cited by 824
Phenotype and function of human T lymphocyte subsets: Consensus and issues
Appay, V., van Lier, R. A. W., Sallusto, F., & Roederer, M. (2008) · Cytometry Part A · doi:10.1002/cyto.a.20643 · Cited by 729 · cited 7×
“We measured cell surface expression of differentiation markers CD62L, CD45RO, CD27, and CD57 (31), inhibitory receptors PD-1, LAG-3, TIM-3, and BTLA, typically expressed on chronically stimulated CD8 + T cells (23, 24, 32, 33), and costimulatory receptor 4-1BB (28, 34) and IL-2 receptor alpha CD25 (35), which can be u…”
BackgroundInfluentialFreeman, G. J., Casasnovas, J. M., Umetsu, D. T., & DeKruyff, R. H. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2010.00903.x · Cited by 614
Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., & Rosenberg, S. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1185 · Cited by 550
Self-citationKaufmann, D. E., Kavanagh, D. G., Pereyra, F., Zaunders, J. J., Mackey, E. W., Miura, T., Palmer, S., Brockman, M., Rathod, A., Piechocka-Trocha, A., et al. (2007) · Nature Immunology · doi:10.1038/ni1515 · Cited by 524
Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?
Akbar, A. N., & Henson, S. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri2959 · Cited by 474 · cited 2×
“Additionally, our present findings showed that the frequency of a specific clonotype in the CD8+ and PD-1+ populations can be used to predict its ability to recognize tumor and isolate tumor-specific TCRs, thus providing means to overcome potential irreversible functional impairments of TILs (52).”
BackgroundRobbins, P. F., Dudley, M. E., Wunderlich, J., El-Gamil, M., Li, Y. F., Zhou, J., Huang, J., Powell, D. J., & Rosenberg, S. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7125 · Cited by 463
Self-citationWolfl, M., Kuball, J., Ho, W. Y., Nguyen, H., Manley, T. J., Bleakley, M., & Greenberg, P. D. (2007) · Blood · doi:10.1182/blood-2006-11-056168 · Cited by 458
Youngblood, B., Oestreich, K. J., Ha, S.-J., Duraiswamy, J., Akondy, R. S., West, E. E., Wei, Z., Lu, P., Austin, J. W., Riley, J. L., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.06.015 · Cited by 419
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
Golden-Mason, L., Palmer, B., Klarquist, J., Mengshol, J. A., Castelblanco, N., & Rosen, H. R. (2007) · Journal of Virology · doi:10.1128/jvi.00409-07 · Cited by 371
Price, D. A., Brenchley, J. M., Ruff, L. E., Betts, M. R., Hill, B. J., Roederer, M., Koup, R. A., Migueles, S. A., Gostick, E., Wooldridge, L., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051357 · Cited by 366
Self-citation4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-1
Lee, H.-W., Park, S.-J., Choi, B. K., Kim, H. H., Nam, K.-O., & Kwon, B. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.4882 · Cited by 363
Zippelius, A., Batard, P., Rubio-Godoy, V., Bioley, G., Liénard, D., Lejeune, F., Rimoldi, D., Guillaume, P., Meidenbauer, N., Mackensen, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3066 · Cited by 361
Immune recognition of a human renal cancer antigen through post-translational protein splicing
Hanada, K.-I., Yewdell, J. W., & Yang, J. C. (2004) · Nature · doi:10.1038/nature02240 · Cited by 336
Self-citationTHE MULTI-SUBUNIT INTERLEUKIN-2 RECEPTOR
Waldmann, T. A. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.004303 · Cited by 329
CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Ye, Q., Song, D.-G., Poussin, M., Yamamoto, T., Best, A., Li, C., Coukos, G., & Powell, D. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0945 · Cited by 322
Role of 4-1BB in immune responses
Vinay, D. S., & Kwon, B. S. (1998) · Seminars in Immunology · doi:10.1006/smim.1998.0157 · Cited by 312
Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges
Wang, C., Lin, G. H. Y., McPherson, A. J., & Watts, T. H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00765.x · Cited by 298
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion
Utzschneider, D. T., Legat, A., Fuertes Marraco, S. A., Carrié, L., Luescher, I., Speiser, D. E., & Zehn, D. (2013) · Nature Immunology · doi:10.1038/ni.2606 · Cited by 283
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y.-X., & Melero, I. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.008 · Cited by 276
Dudley, M. E., Gross, C. A., Somerville, R. P. T., Hong, Y., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.6441 · Cited by 235
Self-citationSelection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells
Inozume, T., Hanada, K.-I., Wang, Q. J., Ahmadzadeh, M., Wunderlich, J. R., Rosenberg, S. A., & Yang, J. C. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fad2b0 · Cited by 233
Self-citationDatabase of T cell-defined human tumor antigens: the 2013 update.
Vigneron, N., Stroobant, V., den Eynde, B. J. V., & van der Bruggen, P. (2013) · Europe PMC (PubMed Central) · Cited by 226
Knabel, M., Franz, T. J., Schiemann, M., Wulf, A., Villmow, B., Schmidt, B., Bernhard, H., Wagner, H., & Busch, D. H. (2002) · Nature Medicine · doi:10.1038/nm0602-631 · Cited by 211
Baitsch, L., Legat, A., Barba, L., Fuertes Marraco, S. A., Rivals, J.-P., Baumgaertner, P., Christiansen-Jucht, C., Bouzourene, H., Rimoldi, D., Pircher, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030852 · Cited by 184
TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients
Kvistborg, P., Shu, C. J., Heemskerk, B., Fankhauser, M., Thrue, C. A., Toebes, M., van Rooij, N., Linnemann, C., van Buuren, M. M., Urbanus, J. H. M., et al. (2012) · OncoImmunology · doi:10.4161/onci.18851 · Cited by 178
Self-citationAdoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay
Becker, C., Pohla, H., Frankenberger, B., Schüler, T., Assenmacher, M., Schendel, D. J., & Blankenstein, T. J. F. (2001) · Nature Medicine · doi:10.1038/nm1001-1159 · Cited by 174
PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status
Sauce, D., Almeida, J. R., Larsen, M., Haro, L., Autran, B., Freeman, G. J., & Appay, V. (2007) · AIDS · doi:10.1097/qad.0b013e3282eee548 · Cited by 174
Self-citationYoungblood, B., Noto, A., Porichis, F., Akondy, R. S., Ndhlovu, Z. M., Austin, J. W., Bordi, R., Procopio, F. A., Miura, T., Allen, T. M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203161 · Cited by 171
Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State
Schietinger, A., Delrow, J. J., Basom, R. S., Blattman, J. N., & Greenberg, P. D. (2012) · Science · doi:10.1126/science.1214277 · Cited by 169
Schwartzentruber, D. J., Hom, S. S., Dadmarz, R., White, D. E., Yannelli, J. R., Steinberg, S. M., Rosenberg, S. A., & Topalian, S. L. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.7.1475 · Cited by 157
Self-citationIoannides, C. G., Freedman, R. S., Platsoucas, C. D., Rashed, S., & Kim, Y. P. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.5.1700 · Cited by 151
Dziubianau, M., Hecht, J., Kuchenbecker, L., Sattler, A., Stervbo, U., Rödelsperger, C., Nickel, P., Neumann, A. U., Robinson, P. N., Mundlos, S., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12431 · Cited by 139
Huang, J., El‐Gamil, M., Dudley, M. E., Li, Y. F., Rosenberg, S. A., & Robbins, P. F. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6057 · Cited by 127
Self-citationTurcotte, S., Gros, A., Hogan, K., Tran, E., Hinrichs, C. S., Wunderlich, J. R., Dudley, M. E., & Rosenberg, S. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300538 · Cited by 107
Self-citationMujib, S., Jones, R. B., Lo, C. C., Aidarus, N., Clayton, K., Sakhdari, A., Benko, E., Kovacs, C. M., & Ostrowski, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102609 · Cited by 105
Early T Cell Signalling Is Reversibly Altered in PD-1+ T Lymphocytes Infiltrating Human Tumors
Renault, S., Fouquet, S., Chapon, M., Salmon, H., Régnier, F., Labroquère, K., Badoual, C., Damotte, D., Validire, P., Maubec, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017621 · Cited by 97
Gros, A., Turcotte, S., Wunderlich, J. R., Ahmadzadeh, M., Dudley, M. E., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1108 · Cited by 88
Self-citationPiersma, S. J., Welters, M. J. P., van der Hulst, J. M., Kloth, J. N., Kwappenberg, K. M. C., Trimbos, B. J. B. M. Z., Melief, C. J. M., Hellebrekers, B. W. J., Fleuren, G. J., Kenter, G. G., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23162 · Cited by 87
CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues
Phan, G. Q., Weber, J. S., & Sondak, V. K. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0104-y · Cited by 60
Lu, Y., Boss, J. M., Hu, S. X., Xu, H., & Blanck, G. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.7.2495 · Cited by 40
Hombrink, P., Hadrup, S. R., Bakker, A., Kester, M. G. D., Falkenburg, J. H. F., Borne, P. A. V. D., Schumacher, T. N., & Heemskerk, M. H. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022523 · Cited by 31
Höhn, H., Neukirch, C., Freitag, K., Necker, A., Hitzler, W. E., Seliger, B., & Maeurer, M. J. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01841.x · Cited by 28
Cited by
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Self-citationImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Metadata
- Authors
- Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., Hanada, K.-I., Almeida, J. R., Darko, S., Douek, D. C., Yang, J. C., & Rosenberg, S. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-03-25
- Volume
- 124
- Issue
- 5
- Pages
- 2246-2259
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1980137951
- Cited by
- 1,111
- References
- 71
- FWCI
- 40.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.